CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Blood plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (3)

Name (Synonyms) Correlation
D019964 Mood Disorders NIH 0.71
D004194 Disease NIH 0.18
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Convalescent Plasma for the Treatment of Moderate-severe COVID-19: A Proof-of-principle Study

The purpose of this proof of concept study is to provide COVID-19 convalescent plasma to patients with moderate to severe COVID-19 and assess: - the titer of anti-COVID-19 antibodies in the donors and in the patients before and after treatment; - the in-depth analysis of immunological parameters in the donors and in recipient before and after treatment; - the impact of plasma transfusion on the reduction of viral load and inflammation - safety and tolerability - clinical efficacy

NCT04365439 Blood Plasma Therapy COVID Biological: Blood plasma

Primary Outcomes

Measure: Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors

Time: At plasma donation

Measure: Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma

Time: Change from baseline at day 21

Measure: Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)

Time: Change from baseline at day 7

Description: Semiquantitative measure of viral load by rtPCR for SARS-CoV-2 by nasopharyngeal swabs, at diagnosis and on day 1,3,7

Measure: Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs

Time: Change from day of diagnosis at day 1

Secondary Outcomes

Description: 7-point ordinal scale measure on day 0 (Baseline), day 1, 3 and 7 after plasma transfusion

Measure: Number of patients with improvement in the 7-points Ordinal Scale

Time: At day 7

Description: AE will be assessed by the DAIDS scale on day 1, 3, 7 and 21. Relatedness with plasma transfusion will also be reported.

Measure: Proportion of patients with adverse events, severity of adverse events

Time: At day 21

No related HPO nodes (Using clinical trials)